Lilly Says Retatrutide More Than Doubles Ozempic Weight Loss in Trial
Eli Lilly said its experimental diabetes and obesity drug retatrutide delivered more than double the weight loss of Novo Nordisk’s Ozempic in a head-to-head trial.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.